Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

Accessibility StatementSkip Navigation In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primarv endpoint In ACHIEVE-5. orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primarv endpoint INDIANAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to- head trial in the program, eval ...